BALB/c mice models implanted with 4 T1 mammary tumor cells were treated with 6‐shogaol (30 mg/kg of body weight) for 14–21 days, decreasing CCL2 in TADCs and reducing metastasis. This evidence concerns the gene CCL2 and breast cancer.